The Brastianos laboratory studies genomic drivers of human brain tumors. A lack of understanding of the molecular drivers of many brain tumors has hampered the development of novel therapies for many brain cancers. Our overarching objective is to characterize molecular drivers of both progression in primary brain tumors and brain metastases, and accelerate the development of novel therapeutic approaches for these diseases.​

John Iafrate, MD, PhD

Dr. Iafrate is the director of the Center for Integrated Diagnostics, a clinical laboratory for molecular diagnostics at Massachusetts General Hospital. He oversees the Translational Research Laboratory (TRL), a shared effort of the Pathology Department and Mass General Cancer Center. Dr. Iafrate received his MD, PhD degrees from the State University of New York at Stony Brook in 2000, and was trained in anatomic and molecular genetic pathology at Brigham and Women's Hospital. He joined the Massachusetts General Hospital staff in 2005. ​
The Suvà laboratory is focused on developing and applying single-cell genomic technologies to dissect the biology of brain tumors, in particular adult and pediatric gliomas. We study patient samples at single-cell resolution and establish genetically and epigenetically relevant cellular models directly from clinical tumors. We model how brain cancer cells exploit their plasticity to establish phenotypically distinct populations of cells, with a focus on programs governing glioma stem cells.